Adrenocortical cancer - the effectiveness of mitotane therapy depending on the time of therapy and the therapeutic dose

SummaryAim: This study was performed to analyse the impact of the choice of antithyroid drugs (ATD) on the outcome of ablative radioiodine therapy (RIT) in patients with Graves' disease. Patients, material, methods: A total of 571 consecutive patients were observed for 12 months after RIT between July 2001 and June 2004. Inclusion criteria were the confirmed diagnosis of Graves' disease, compensation of hyperthyroidism and withdrawal of ATD two days before preliminary radioiodine-testing and RIT. The intended dose of 250 Gy was calculated from the results of the radioiodine test and the therapeutically achieved dose was measured by serial uptake measurements. The end-point measure was thyroid function 12 months after RIT; success was defined as elimination of hyperthyroidism. The pretreatment ATD was retrospectively correlated with the results achieved. Results: Relief from hyperthyroidism was achieved in 96 % of patients. 472 patients were treated with carbimazole or methimazole (CMI) and 61 with propylthiouracil (PTU). 38 patients had no thyrostatic drugs (ND) prior to RIT. The success rate was equal in all groups (CMI 451/472; PTU 61/61; ND 37/38; p=0.22). Conclusion: Thyrostatic treatment with PTU achieves excellent results in ablative RIT, using an accurate dosimetric approach with an achieved post-therapeutic dose of more than 200 Gy.

Download Full-text

EFFECT OF KAGOCEL PREPARATION ON THE GENERATIVE FUNCTION OF EXPERIMENTAL ANIMALS AT ITS ADMINISTRATION IN THE INFANTILE PERIOD OF THEIR DEVELOPMENT

Токсикологический вестник ◽

10.36946/0869-7922-2017-3-42-49 ◽

2017 ◽

pp. 42-49

Author(s):

T. A. Borovskaya ◽

M. E. Poluektova ◽

A. V. Vychuzhanina ◽

V. A. Mashanova ◽

Yu. A. Shchemerova

Keyword(s):

Toxic Effect ◽

Reproductive System ◽

Safety Profile ◽

Therapeutic Dose ◽

Antiviral Drug ◽

Experimental Studies ◽

Reproductive Age ◽

Pathological Changes ◽

Pediatric Practice ◽

Experimental Animals

In experimental studies on rats (males, females) at their infantile stage starting from 10 days, a potential delayed toxic effect of the antiviral drug Kagocel on the reproductive system was studied. The drug was administered for 12 days in a therapeutic dose and at a dose 10-fold higher than the therapeutic one. Reproductive safety was estimated after animals reached the reproductive age (2.5 months). It was found out that the drug, when administered in both doses, does not decrease the fertility of animals, does not induce morphological and pathological changes in the sex glands, and does not have toxic effect on the offspring. Obtained data characterize Kagocel as a preparation with a wide reproductive safety profile and show that it can be used in pediatric practice for infants.

Download Full-text

SIRT1 is involved in adrenocortical cancer growth and motility

Journal of Cellular and Molecular Medicine ◽

10.1111/jcmm.16317 ◽

2021 ◽

Author(s):

Adele Chimento ◽

Arianna De Luca ◽

Marta Claudia Nocito ◽

Sara Sculco ◽

Paola Avena ◽

...

Keyword(s):

Cancer Growth ◽

Adrenocortical Cancer

Download Full-text

Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation

Scientific Reports ◽

10.1038/s41598-021-85234-1 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Ryo Yamazaki ◽

Osamu Nishiyama ◽

Sho Saeki ◽

Hiroyuki Sano ◽

Takashi Iwanaga ◽

...

Keyword(s):

Risk Factors ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Therapeutic Dose ◽

Early Recurrence ◽

Time To Recurrence ◽

Acute Exacerbations ◽

Patient Groups ◽

The Mean ◽

Mean Time

AbstractSome patients with idiopathic pulmonary fibrosis (IPF) undergo recurrent acute exacerbations (AEs). This study aimed to elucidate the risk factors for recurrent AEs of IPF (AE-IPF). Consecutive patients with IPF admitted for their first AE-IPF between January 2008 and December 2018 were retrospectively recruited. Of 63 patients admitted for an AE-IPF and discharged alive, 9 (14.3%) developed a recurrence of AE within 1 year. The mean time to recurrence was 233 ± 103 days. Total doses (mg/month and mg/kg/month) of corticosteroids administered over day 1 to 30 after the AE were significantly higher in patients without recurrences of AE-IPF (5185 ± 2414 mg/month, 93.5 ± 44.0 mg/kg/month) than the doses in patients with recurrences (3133 ± 1990 mg/month, 57.2 ± 37.7 mg/kg/month) (p = 0.02 and p = 0.03, respectively). However, no differences were observed between the total doses of corticosteroids administered over days 31 to 60, 61 to 90, 91 to 120, and 151 to 180 after the AE. Furthermore, differences between the administration rates of immunosuppressive and antifibrotic treatments administered to the 2 patient groups were not significant. An increased total dose of corticosteroid administered over day 1 to 30 after an AE-IPF was associated with a decreased risk of subsequent recurrence of AE-IPF within 1 year after the first AE.

Download Full-text